Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

The bottom five are (in order from steepest price decline to narrowest): Walgreens Boots Alliance (NASDAQ: WBA), Estée Lauder ...

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters -- they're not just another dose of ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...